budoprutug — Clinical data readout
Late 2026
The Company expects to announce additional data from the study by year-end 2026.Source filing
CLYM biotech catalysts & pipeline
CLIMB BIO INC · Data as of 2026-10-25
Upcoming catalysts
budoprutug — Initial data
Q4 2026
Anticipate data, including safety and biomarker data from the Global study in the fourth quarter of 2026.Source filing
budoprutug — Initial data
2027
Plan to initiate a multiple-dose study of the SC formulation in autoimmune patients; anticipate initial data in 2027.Source filing
CLYM116 — Initial data
H1 2027
Initial data from NAVIGATE-2 Phase 2 anticipated in the first half of 2027Source filing
CLYM116/MIL116 — Initial data
H1 2027
The NAVIGATE-2 Phase 2 trial is currently enrolling IgAN patients to confirm the Q12W dosing regimen, and a global Phase 3 trial is expected to initiate in 2027, pending regulatory feedback.Source filing
budoprutug — Conference presentation
Oct 21–Oct 25
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and BudoprutugSource filing
CLYM116 — Conference presentation
Oct 21–Oct 25
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and BudoprutugSource filing